Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CLL
•
CML
•
Hematology
How would you treat CML and CLL that occurred together?
Related Questions
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?
If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Does treating CLL reduce the risk of non-melanoma skin cancers?
